Catalysts / KYTX
Upcoming FDA decisions and readouts we track for Kyverna Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Kyverna Therapeutics (KYTX, listed on Nasdaq). Both concern Miv-cel (mivotacel) (Stiff person syndrome; Progressive multiple sclerosis).
First on the list: the Phase 2 readout for Miv-cel (mivotacel) (Stiff person syndrome), guided by the company to Q3 2026. By stage, the upcoming rows are 1 Phase 1 readout and 1 Phase 2 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics KYTX · Nasdaq | Miv-cel (mivotacel) | Stiff person syndrome | Q3 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Kyverna Therapeutics KYTX · Nasdaq | Miv-cel (mivotacel) | Progressive multiple sclerosis | Q4 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList